(CercleFinance.com) – Sartorius Stedim Biotech sells 1% after the conclusion, by the supplier to the pharmaceutical industry, of the acquisition of the chromatography division of Novasep, a transaction which leads it to adjust its forecast of business for 2022.
The acquired business generated revenue of approximately €40 million in 2020 with a double-digit profit margin. It employs around a hundred people, who work mainly in France, but also in the United States, China and India.
At constant exchange rates, Sartorius Stedim Biotech now expects revenue growth between 15 and 19% (previously 14-18%), while the company’s current EBITDA margin is still expected to be more than 35 % This year.